BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

NCT00126646 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Lymphoma

Interventions

DRUG: BL22 immunotoxin
PROCEDURE: antibody-drug conjugate therapy
PROCEDURE: immunotoxin therapy

Sponsor

MedImmune LLC